29/05/2024 – AB Science today announces that the CHMP adopted a trending toward a negative opinion on the application for conditional marketing authorisation of masitinib in ALS Download PDF Post navigationPreviousPrevious post:Corrective statement on the consolidated accounts as of December 31, 2023NextNext post:AB Science webcast of May 30, 2024Related PostsPositive results of the Phase 2 study evaluating masitinib in Covid-19July 8, 2024AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSJune 28, 2024June 26, 2024 CGM – Q&A documentJune 26, 2024Summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALSMay 31, 2024AB Science webcast of May 30, 2024May 30, 2024Corrective statement on the consolidated accounts as of December 31, 2023May 17, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSJune 28, 2024
Summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALSMay 31, 2024
